Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing determines nuclear-accumulated Cav3.2iPA on transcriptional regulation of human iPSC-derived sensory neurons

ABSTRACT: By targeting the intrinsically disordered regions (IDR) of calcium channel subtype 3.2 (Cav3.2), we discovered selective T-type/Cav3.2 peptide inhibitors (Cav3.2iPAs) for AAV-mediated peripheral sensory neuron-specific analgesia. We found that Cav3.2iPAs are highly accumulated in the nuclei after expression in human induced pluripotent stem cells-derived sensory neurons (hiPSC-SNs). This study aims to determine whether nuclear-accumulated Cav3.2iPAs disturb the transcriptional regulation of hiPSC-SNs which becomes a safety concern.

ORGANISM(S): Homo sapiens

PROVIDER: GSE266367 | GEO | 2024/05/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

iPSC-derived human sensory neurons reveal a subset of TRPV1 antagonists as anti-pruritic compounds

Project description:Given the inaccessibility of human sensory neurons (SNs), it is yet to be established whether the signalling pathway between histamine 1 receptor (H1R) and transient receptor potential cation channel subfamily V member 1 (TRPV1) is conserved between humans and mammalian models. Accessible human SNs are vital for identifying TRPV1 antagonists with higher potential for success in clinical trials targeting histaminergic itch, especially given TRPV1's species specificity concerns. Hence to build a humanized histamine-dependent itch model, we derived peripheral sensory neurons from human pluripotent stem cells (hiPSC-SNs) and validated channel functionality using immunostaining, calcium imaging and multielectrode array (MEA) recordings. Here, we demonstrated that a subset of hiPSC-SNs exhibits co-expression of H1R and TRPV1, responding to both histamine and capsaicin agonists. We found that inhibiting TRPV1 prevented histamine activation. Moreover, we show that silencing histamine-sensitive neurons reduces capsaicin response, and silencing capsaicin-sensitive neurons diminishes histamine response. To assess the ability of hiPSC-SNs in TRPV1 antagonist drug screening, we evaluated two well-established hyperthermic and three thermal-neutral TRPV1 antagonists. Our finding identifies SB366791, a thermal-neutral antagonist, as a potent inhibitor of H1R activation. The use of hiPSC-SNs may therefore provide a physiologically relevant means to perform large-scale screening to discover anti-pruritic agents predictive of actual efficacy in human clinical trials.

2024-02-27 | GSE256435 | GEO

study on accumulated dust ARGs

Project description:study on accumulated dust ARGs

| PRJEB51402 | ENA

study on accumulated dust ARGs

Project description:study on accumulated dust ARGs

| PRJEB51418 | ENA

study on accumulated dust ARGs

Project description:study on accumulated dust ARGs

| PRJEB51419 | ENA

study on accumulated dust ARGs

Project description:study on accumulated dust ARGs

| PRJEB52154 | ENA

RNA sequencing determines nuclear-accumulated Cav3.2iPA on transcriptional regulation of human iPSC-derived sensory neurons

Project description:RNA sequencing determines nuclear-accumulated Cav3.2iPA on transcriptional regulation of human iPSC-derived sensory neurons

| PRJNA1106834 | ENA

Transcription profiling of SNS-gp130-/- vs control mice

Project description:To analyze the effect of Glycoprotein 130 in small diameter sensory neurons, dorsal root ganglia (DRG) of conditional SNS-gp130-/- and control (gp130fl/fl) mice were collected and mRNA expression profiles were compared between the two groups. DRG samples of two littermate mice were always pooled and a total of 10 gp130fl/fl and 10 SNS-gp130-/- mice were divided into 5 groups per genotype. Expression of transcripts were analyzed using the Applied Biosystems microarray platform AB1700 (Mouse Genome Survey Microarray V2.0).

2014-08-04 | E-MTAB-2584 | biostudies-arrayexpress

Exploratory research on online complete system construction from colorectal cancer screening recommendation to detailed examination recommendation using SNS

Project description:Primary outcome(s): Research participation consent rate by website inflow source/ 1)Influx of natural search (click directly to the site with Google search, etc.) 2)Paid search influx 2.1)Google 2.2)Youtube 3) infllux with SNS 3.1)Line 3.2)Facebook 3.3) Health awareness game(Unkore:http://unkore.jp/) 3.4) Peerring (https://peer-ring.com/) 4) others (Personal blog ,etc.)

| 2739060 | ecrin-mdr-crc

Lipid-accumulated reactive astrocytes promote seizure activity in epilepsy

Project description:Lipid-accumulated reactive astrocytes promote seizure activity in epilepsy

| PRJNA787216 | ENA

Gene expression in GBM with Cav3.2 inhibition

Project description:Glioblastoma stem cells (GSCs) have been implicated in tumor initiation, progression and resistance to therapy. We investigated the expression, function, mechanisms of action and therapeutic targeting of T-type calcium channels (Cav3.2) with the FDA approved and repurposed drug mibefradil in glioblastoma (GBM), and GSCs. We found that Cav3.2 is highly expressed in human GBM specimens and enriched in GCSs. Analyses of TCGA and REMBRANDT databases confirmed the upregulation of Cav3.2 in a subset of tumors (TCGA) and showed that overexpression is associated with worse prognosis. Mibefradil and Cav3.2 knockdown inhibited the growth, survival and stemness of GSCs and sensitized them to temozolomide (TMZ) chemotherapy. To investigate the mechanisms of action of Cav3.2 in GSC, we performed proteomic and transcriptomic screenings followed by functional rescue experiments. Inhibition of Cav3.2 altered cancer signaling pathways and gene transcription. Among other, inhibition of Cav3.2 suppressed GSC growth through inhibition of pro-survival pathways AKT/mTOR, and induction of apoptosis through upregulation of survivin, BAX and cleavage of caspase 9 and PARP. Inhibition of Cav3.2 induced a decrease in the expression of oncogenes including PDGFA, PDGFB and TGFB1 and an increase in the expression of tumor suppressors including TNFRSF14 and HSD17B14. In vivo oral administration of Cav3.2 blocker mibefradil significantly inhibited GSC-derived xenograft growth, prolonged animal survival and sensitized the tumors to TMZ. Our study represents the first comprehensive characterization of Cav3.2 in GBM tumors and GSC. The findings establish Cav3.2 inhibition with the repurposed FDA-approved drug mibefradil as a new strategy for GBM therapy.

2017-08-31 | GSE95106 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data